October 2026 brought 52-week data for oral denifanstat, U.S. over-the-counter access to adapalene-benzoyl peroxide, and updated acne guidelines from NICE and EuroGuiDerm. Durable pill results matter for severe acne, while readers should watch U.S.
trial enrollment and store availability of the OTC gel. Denifanstat is a once-daily oral FASN inhibitor. It blocks an enzyme that helps make sebum fats. Less sebum means fewer clogged pores and inflammatory lesions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is a new oral drug getting closer?
- What can you buy without a prescription now?
- How have rules and guidelines shifted?
- Who needs closer follow-up after isotretinoin?
Is a new oral drug getting closer?
Sagimet Biosciences announced 56.7% treatment success and 71.8% mean total-lesion reduction through up to 52 weeks in moderate-to-severe acne. The Phase 3 ASC40-304 open-label extension was run by licensee Ascletis and presented at EADV Vienna Sept. 30-Oct. 3, 2026, full 52-week results. The drug targets sebum directly from inside the body. That differs from antibiotics, retinoids, and hormonal drugs. No new oral class has reached acne care in decades.
U.S. testing is the next step. Clinical Trial Vanguard reported an FDA Study May Proceed letter on Aug. 13, 2026 for moderate-to-severe acne. Sagimet reported via BioSpace that all AURORA Phase 3 sites were identified, with screening expected in October 2026 and first enrollment soon after. Dermatology Times reported the key limit: the 52-week result is open-label without placebo and was run in China, so durability and U.S. fit await AURORA, sustained benefit analysis. Readers cannot get denifanstat by prescription yet.
What can you buy without a prescription now?
Galderma announced FDA approval for Differin Epiduo Gel for over-the-counter use in ages 12 and older. The gel pairs adapalene 0.1% with benzoyl peroxide 2.5%, OTC switch approval. Adapalene clears pores and calms inflammation. Benzoyl peroxide kills acne bacteria and limits resistance.
The switch expands access for teens and adults with mild-to-moderate acne. It removes a clinic visit for this fixed combination. It does not replace care for severe, scarring, or rapidly worsening acne. Use one pea-sized layer as directed once daily:.
- cleanse gently, pat dry, then apply a thin film
- start every other night if burning or peeling occurs
- add moisturizer and morning sunscreen during use
How have rules and guidelines shifted?
The National Institute for Health and Care Excellence amended acne guideline NG198. It removed the need for two independent professionals to approve isotretinoin in under-18s. Severity and safety checks still apply, but initiation is simpler. Nast and colleagues published the EuroGuiDerm evidence-based acne update on March 18, 2026.
It replaces the 2016 version. It prioritizes choice between isotretinoin and antibiotics, shorter antibiotic courses, hormonal therapy, and placement of clascoterone and trifarotene to curb resistance. For readers, the message is practical. Ask how long an antibiotic is planned and what topical will maintain gains. Ask whether isotretinoin, hormonal care, or a newer topical fits the pattern.
Who needs closer follow-up after isotretinoin?
A Sept. 14, 2026 Frontiers in Endocrinology cohort studied severe acne after oral isotretinoin. Baseline high free-androgen index, high DHEA-sulfate, and metabolic markers predicted recurrence. Androgens are hormones that raise sebum. DHEA-sulfate is an adrenal androgen measured in blood.
The finding supports closer follow-up for hyperandrogenic patients. It does not support routine hormone testing for everyone. People with irregular periods, excess hair growth, hair shedding, or rapid relapse should tell their clinician. Track return for three to six months after the course ends. Note lesion count, period pattern, weight change, and new hair growth. Bring that log to the follow-up visit before restarting treatment.